<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en-US">
	<head>
		<meta charset="utf-8" />
		<title>BCSC2025-26_S08_C09_p213_236_4P</title>
		<link href="BCSC2025-26_S08_C09_p213_236_4P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC2025-26_S08_C09_p213_236_4P">
		<div id="_idContainer016" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">CHAPTER</span><span class="cn-chap"> </span>9</p>
			<p class="chapter-title">Clinical Approach to Corneal Ectatic Disease</p>
			<p class="video-list-mid ParaOverride-1">
			<!--<img class="_idGenObjectAttribute-1" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/bcsc-2025-26-video-icon-boilerplate.jpg" alt="" />&#9;-->
			This chapter includes related videos. <span class="video-list_italic">Go to</span> <a target="_blank" href="http://aao.org/bcscvideo_section08"><span class="video-list_italic">aao.&#173;org/&#173;bcscvideo_&#173;section08</span></a> <span class="video-list_italic">or scan the QR codes in the text to access this content.</span></p>
			<p class="video-list-mid ParaOverride-2">
			<!--<img class="_idGenObjectAttribute-2" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/bcsc-2025-26-case-study-icon-boilerplate.jpg" alt="" />&#9;-->
			This chapter includes a case study. <span class="video-list_italic">Go to</span> <a target="_blank" href="http://aao.org/bcsccasestudy_section08"><span class="video-list_italic">aao.&#173;org/&#173;bcsccasestudy_&#173;section08</span></a> <span class="video-list_italic">or scan the QR code in the text to access this content.</span></p>
			<p class="video-list-mid ParaOverride-3">
			<!--<img class="_idGenObjectAttribute-3" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/bcsc-2025-26-keypoint-icon-boilerplate.jpg" alt="" />&#9;-->
			<span class="video-list_italic">Indicates selected key points within the chapter.</span></p>
			
			<p class="h1">Introduction</p>
				<div id="Chapt9_Top1">
					<p class="body-text--no-indent-"><span class="italic">Corneal ectasia</span> is defined as progressive corneal steepening and thinning. Ectatic diseases include keratoconus, pellucid marginal degeneration, keratoglobus, and ectasia &#173;after corneal refractive surgery (eg, &#173;laser in situ keratomileusis [LASIK] or photorefractive keratectomy [PRK]). Corneal ectasias can cause decreased uncorrected and corrected distance and near visual acuity and are often associated with irregular astigmatism, astigmatism in which the principal meridians are not orthogonal.</p>
					<p class="reference-first">Jhanji&#160;V, Ahmad&#160;S, Amescua&#160;G, et&#160;al; American Acad&#173;emy of Ophthalmology Preferred Practice Pattern Cornea/External Disease Panel. Corneal Ectasia Preferred Practice Pattern. <span class="reference_italic">Ophthalmology.</span> 2024;131(4):P205–&#173;P246. <a target="_blank" href="https://doi.org/10.1016/j.ophtha.2023.12.038">doi:10.1016/j.ophtha.2023.12.038</a></p>
				</div>
			
			<p class="h1">Keratoconus</p>
				<div id="Chapt9_Top2">
					<p class="body-text--no-indent-">Keratoconus (KC) is a common ectatic disorder in which the central, inferior paracentral, or inferior midperipheral cornea typically undergoes progressive thinning and protrusion, resulting in a cone-&#173;shaped cornea (<span class="xref-figure" id="Fig 9-1">Figs&#160;9-1</span>, <span class="xref-figure" id="Fig 9-2">9-2</span>). The prevalence of KC has been reported to be between 1:2000 and 1:375. However, the incidence rate varies on the basis of geographic location and the testing methodology. A higher incidence has been reported in South Asian and &#173;Middle Eastern countries than elsewhere.</p>
					<p class="body-text">&#173;Factors that may play a role in the onset and progression of KC include</p>
					<ul>
						<li class="bullet-list-first">ge&#173;ne&#173;tic predisposition</li>
						<li class="bullet-list-mid">eye rubbing</li>
						<li class="bullet-list-mid">young age</li>
						<li class="bullet-list-mid">atopic disease and allergic keratoconjunctivitis</li>
						<li class="bullet-list-mid">abnormalities in collagen that result in hyperelastic joints</li>
						<li class="bullet-list-last">ablative keratorefractive surgery in patients with high preoperative myopia, thin corneas, or abnormal findings on tomography</li>
					</ul>
					<p class="body-text">Although a hereditary pattern is not commonly observed in KC, positive &#173;family histories have been reported in 6%–8% of cases, with a prevalence of 3.34% in first-&#173;degree relatives. Considerable variations in clinical findings can occur within an affected &#173;family. <span class="keypoint_underline">In addition, clinically unaffected first-&#173;degree relatives have a higher chance of showing subclinical tomographic abnormalities associated with KC than the general population.</span> Although multiple chromosomal loci for KC have been reported, the identification of specific genes remains elusive.</p>
					<!--<div class="_idGenObjectLayout-1">
						<div id="_idContainer003" class="keypoint-l">
							<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/bcsc-2025-26-keypoint-icon-interior.jpg" alt="" />
						</div>
					</div>-->
					<p class="clinical-pearl ParaOverride-4"><span class="sidebar2-head"><span class="sidebar-text_bold">Clinical Pearl</span></span><span class="sidebar2-head"> </span>Clinicians should consider the possibility of keratoconus in young patients who require frequent changes in their eyeglass prescription &#173;because of increased myopia and astigmatism or whose refractive error cannot be fully corrected with glasses.</p>
					<p class="body-text">KC onset occurs during puberty. The rate of progression of KC is highest in young individuals (in their teens and twenties); its development should be closely monitored in this subpopulation as vision may worsen and disease progression can be arrested or slowed with corneal crosslinking. Progression typically slows in the fourth &#173;decade of life, although it may continue to pro&#173;gress. However, development of KC &#173;after the age of 40&#160;years is unusual.</p>
					<p class="body-text">KC has been found to be associated with immune-&#173;mediated diseases such as atopic dermatitis, Hashimoto thyroiditis, inflammatory skin conditions, asthma, and allergic rhinitis. KC is commonly observed in Down syndrome and other conditions associated with developmental delay; in disorders associated with skin hyperelasticity, such as Ehlers-&#173;Danlos syndrome; and in patients with low vision, prob&#173;ably &#173;because of habitual eye rubbing. <span class="xref-table" id="Table 9-1">&#173;Table&#160;9-1</span> pre&#173;sents common systemic and ocular associations with KC.</p>
					<p class="body-text">In addition, corneal ectasia can occur &#173;after ablative keratorefractive surgery such as LASIK or PRK. Risk &#173;factors include young age, high preoperative myopia, thin residual stromal bed, thin preoperative cornea, and abnormal preoperative contour.</p>
					<p class="reference-first">Claessens&#160;JLJ, Godefrooij&#160;DA, Vink&#160;G, Frank&#160;LE, Wisse&#160;RPL. Nationwide epidemiological approach to identify associations between keratoconus and immune-&#173;mediated diseases. <br /><span class="reference_italic">Br J&#160;Ophthalmol.</span> 2022;106(10):1350–1354.</p>
					<p class="reference-mid">Feder&#160;RS, Le H-&#173;G. Noninflammatory ectatic disorders. In: Mannis&#160;MJ, Holland&#160;EJ, <br />eds. <span class="reference_italic">Fundamentals, Diagnosis and Management.</span> 5th&#160;ed. Elsevier; 2022:749–770. <br /><span class="reference_italic">Cornea;</span> vol 1.</p>
					<p class="reference-mid">Godefrooij&#160;DA, de Wit&#160;GA, Uiterwaal&#160;CS, Imhof&#160;SM, Wisse&#160;RP. Age-&#173;specific incidence and prevalence of keratoconus: a nationwide registration study. <span class="reference_italic">Am J&#160;Ophthalmol.</span> 2017;175:169–72.</p>
					<p class="h2">Clinical &#173;Presentation</p>
					<p class="body-text--no-indent-">Although KC is typically bilateral, asymmetry is also observed. Apical thinning with protrusion or anterior bowing of the inferior paracentral or midperipheral cornea worsens with disease progression, as does the degree of irregular astigmatism. Generally, keratitis and corneal neovascularization are not observed; however, they may occur due to contact lens wear.</p>
					<p class="body-text">Common signs of KC include</p>
					<ul>
						<li class="bullet-list-first"><span class="bullet-list_italic">scissoring of the light reflex on retinoscopy:</span> an early but nonspecific sign of KC; commonly associated with irregular astigmatism (<span class="bullet-list_xref-video">Video&#160;9-1</span>)</li>
						<li class="bullet-list-mid"><span class="bullet-list_italic">Munson sign:</span> a late-&#173;stage nonspecific sign involving inferior deviation of the lower-&#173;eyelid contour on downgaze (<span class="bullet-list_xref-figure xref-figure" id="Fig 9-3">Fig&#160;9-3</span>)</li>
						<li class="bullet-list-mid"><span class="bullet-list_italic">Rizzuti sign:</span> focusing of the light within the nasal limbus when a penlight is shone from the temporal side; an early but nonspecific sign</li>
						<li class="bullet-list-mid"><span class="bullet-list_italic">Fleischer ring, partial or complete:</span> a brown-&#173;colored ring found at the base of the cone formed by the deposition of iron within the basal epithelium, which becomes narrower and increasingly well-&#173;defined with disease progression. It is best seen with the slit lamp using a broad, oblique beam (<span class="bullet-list_xref-figure xref-figure" id="Fig 9-4">Fig&#160;9-4</span>) or diffuse illumination with the cobalt blue filter.</li>
						<li class="bullet-list-mid"><span class="bullet-list_italic">Vogt striae:</span> fine, parallel lines observed in the posterior stroma at the apex of the cone, which may dis&#173;appear with the application of external pressure (see <span class="bullet-list_xref-figure">Fig&#160;9-4</span>)</li>
						<li class="bullet-list-mid"><span class="bullet-list_italic">apical scarring:</span> types commonly seen include<ul><li class="bullet-list-sub-bullet-list _idGenParaOverride-1">reticular scarring related to breaks in Bowman layer (<span class="bullet-list-sub-bullet-list_xref-figure xref-figure" id="Fig 9-5">Fig&#160;9-5</span>)</li><li class="bullet-list-sub-bullet-list _idGenParaOverride-1">nummular scarring at the cone apex related to contact lens wear (<span class="bullet-list-sub-bullet-list_xref-figure xref-figure" id="Fig 9-6">Fig&#160;9-6</span>)</li>
						<li class="bullet-list-sub-bullet-list _idGenParaOverride-1">deep stromal scarring related to prior corneal hydrops
							<p class="QR-code-caption-first _idGenParaOverride-2">
								<span class="QR-code-number">VIDEO&#160;9-1</span> 
								Scissoring seen with retinoscopy.
							</p>
							<!--<div id="_idContainer004" class="video-r _idGenObjectStyleOverride-1">
								<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/bcsc-2025-26-video-icon-interior.jpg" alt="" />
							</div>-->
							<div id="_idContainer005" class="video-r _idGenObjectStyleOverride-1">
								<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/qr-BCSC25_S08_09-01.jpg" alt="" />
							</div>
							<p class="QR-code-source_left ParaOverride-5">
								<span class="qr-code-source_italic">Original animation developed by Thomas&#160;F.&#160;Mauger, MD; retinoscopy scissoring <br />by Robert&#160;S.&#160;Feder, MD.</span>
							</p>
							<p class="QR-code-source _idGenParaOverride-3">
								Available at: <a target="_blank" href="http://aao.org/bcscvideo_section08">aao.&#173;org/&#173;bcscvideo_&#173;section08</a>
							</p>
						</li></ul></li>
					</ul>
					<p class="body-text">Acute hydrops is the sudden onset of corneal edema that results from rupture of Descemet membrane (<span class="xref-figure" id="Fig 9-7">Fig&#160;9-7)</span> and is usually observed late in the disease course. Risk &#173;factors include allergy and severe eye rubbing (eg, in Down syndrome). Spontaneous perforation in KC is rare. Corneal edema typically clears within 3 months but can lead to posterior stromal scarring. Occasionally, stromal clefts can be seen in association with hydrops; &#173;these clefts usually close but may result in corneal neovascularization.</p>
					<p class="body-text"><span class="xref-video">Video&#160;9-2</span> demonstrates how intensely many patients with KC rub their eyes. <span class="keypoint_underline">It is impor&#173;tant to caution &#173;these patients against eye rubbing &#173;because it contributes to disease progression in addition to the risk of hydrops in advanced cases.</span></p>
					<div class="_idGenObjectLayout-1">
						<div id="_idContainer006" class="keypoint-l">
							<!--<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/bcsc-2025-26-keypoint-icon-interior.jpg" alt="" />-->
						</div>
					</div>
					<p class="QR-code-caption-first_right"><span class="QR-code-number">VIDEO&#160;9-2</span> Vigorous eye rubbing in keratoconus.</p>
					<div class="_idGenObjectLayout-1">
						<!--<div id="_idContainer007" class="video-r _idGenObjectStyleOverride-1">
							<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/bcsc-2025-26-video-icon-interior1.jpg" alt="" />
						</div>-->
					</div>
					<div class="_idGenObjectLayout-1">
						<div id="_idContainer008" class="video-r _idGenObjectStyleOverride-1">
							<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/qr-BCSC25_S08_09-02.jpg" alt="" />
						</div>
					</div>
					<p class="QR-code-source-right ParaOverride-1"><span class="qr-code-source_italic">Courtesy of David&#160;D.&#160;Verdier, MD.</span></p>
					<p class="QR-code-source-right ParaOverride-6">Available at: <a target="_blank" href="http://aao.org/bcscvideo_section08">aao.&#173;org/&#173;bcscvideo_&#173;section08</a></p>
					<p class="h2">Evaluation</p>
					<p class="body-text--no-indent-">Although keratometry can be used to detect both irregular astigmatism and inferior steepening with the patient in upgaze, clinicians depend on more sophisticated technology to evaluate corneal contour. The development of sophisticated topographic (power mapping) and tomographic (elevation and thickness mapping) devices has dramatically improved the detection of corneal ectasia. In par&#173;tic&#173;u&#173;lar, corneal topography and tomography have become indispensable for early diagnosis of KC, tracking its progression, fitting contact lenses, and managing the care of the postoperative patient.</p>
					<p class="body-text"><span class="italic">Topographic findings</span>—&#173;obtained through Placido-&#173;based imaging (reflection of concentric rings), scanning-&#173;slit devices, Scheimpflug imaging, or optical coherence tomography (OCT)–&#173;based devices (see <span class="xref-local">Chapter&#160;2</span>)—&#173;include</p>
					<ul>
						<li class="bullet-list-first">increased overall steepening (<span class="bullet-list_symbol">&gt;</span>47.20 diopters [D])</li>
						<li class="bullet-list-mid">inferior steepening, especially when coincident with abnormal elevation and/or abnormal inferior thinning (<span class="bullet-list_xref-figure" id="Fig 9-8">Figs&#160;9-8</span>, <span class="xref-figure" id="Fig 9-9">9-9</span>, <span class="xref-figure" id="Fig 9-10">9-10</span>)</li>
						<li class="bullet-list-mid">superior flattening (see Figs&#160;9-8, 9-9A)</li>
						<li class="bullet-list-mid">increase in inferior-&#173;superior (I-&#173;S) ratio (I-S <span class="bullet-list_symbol">&gt;</span>1.2 is considered significant) (see Fig&#160;9-9A)</li>
						<li class="bullet-list-last">skewing of the radial axes <span class="bullet-list_symbol">&gt;</span>21°, which is considered suggestive of KC (unlike an orthogonal bow-&#173;tie pattern, which is typical of regular astigmatism; see <span class="bullet-list_xref-local">Chapter&#160;2</span>, Fig&#160;2-13)</li>
					</ul>
					<p class="body-text">Bow-&#173;tie asymmetry without skewing might be attributed to a decentered apex and thus is not pathognomonic of KC. The bow-&#173;tie pattern is ultimately lost as the disease progresses (see Fig&#160;9-8). Therefore, it is best not to rely solely on the power map when evaluating corneal contour.</p>
					<p class="body-text"><span class="italic">Tomographic findings,</span> obtained with scanning-&#173;slit devices, Scheimpflug imaging, or anterior segment OCT (see <span class="xref-local">Chapter&#160;2</span>), include</p>
					<ul>
						<li class="bullet-list-first">isolated islands of elevation anteriorly and/or posteriorly: The elevation maps indicate areas of the patient’s anterior and posterior cornea that are elevated or depressed relative to corresponding areas of their best-&#173;fit spheres (see <span class="bullet-list_xref-local">Chapter&#160;2</span>) (see Figs&#160;9-8, 9-9A)</li>
						<li class="bullet-list-mid">asymptomatic posterior elevation: an early sign of subclinical KC</li>
						<li class="bullet-list-mid">abnormal thinning (<span class="bullet-list_symbol">&lt;</span>500&#160;µm): typical in ectasia, especially when coincident with islands of elevation (see Figs&#160;9-8, 9-9A)</li>
						<li class="bullet-list-mid">I-&#173;S difference of <span class="bullet-list_symbol">&gt;</span>30&#160;µm in thickness at the 5-mm ring around the fixation point</li>
						<li class="bullet-list-mid">difference of <span class="bullet-list_symbol">&gt;</span>30&#160;µm between the 2 eyes in the thinnest pachymetric reading</li>
						<li class="bullet-list-mid">decentration of the thinnest part of the cornea on a pachymetry map (see Fig&#160;9-8); normally, the thinnest cornea is centrally located</li>
						<li class="bullet-list-mid">enhanced ectasia risk, detected by comparing the difference between standard anterior and posterior elevation maps and maps in which the best-&#173;fit sphere is determined, excluding a 4-mm area around the thinnest cornea</li>
						<li class="bullet-list-last">change in corneal thickness, evaluated from the thinnest part of the cornea to the limbus (occurs more dramatically in eyes with KC than in eyes without KC); see <span class="bullet-list_xref-local">Chapter&#160;2</span>, Figure&#160;2-17.</li>
					</ul>
					<p class="body-text"><span class="italic">Anterior segment OCT</span> is used to map corneal epithelial thickness for early diagnosis and follow-up of KC. The normal corneal epithelium is thicker centrally and thinner superiorly, whereas the keratoconic cornea is thinner at the apex of the cone, typically inferotemporally, and thicker superonasally (see Fig&#160;9-9B). &#173;These findings correlate well with ectatic changes observed using other corneal tomography devices. In contact lens–&#173;induced warpage, an increase in the epithelial thickness of the central cornea is observed.</p>
					<p class="body-text">To determine &#173;whether ectatic changes are stable or progressive or if subclinical or suspected KC has progressed and is likely to become symptomatic, serial imaging is necessary. &#173;These images can be used for <span class="italic">KC staging</span>. One staging method is the Belin ABCD keratoconus grading system with progression display unique to Pentacam (Oculus). The ABCD system uses the degree of anterior and posterior curvature at the 3-mm zone centered on the thinnest part of the cornea along with the thinnest pachymetry &#173;measurements and corrected distance visual acuity (CDVA) (entered manually). Once recorded, &#173;these values can be tracked over time. Other Scheimpflug systems can also be used for staging and progression analy&#173;sis. Older staging methods are less helpful &#173;because they predated modern corneal imaging technology.</p>
					<div class="_idGenObjectLayout-1">
						<div id="_idContainer009" class="keypoint-l">
							<!--<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/bcsc-2025-26-keypoint-icon-interior.jpg" alt="" />-->
						</div>
					</div>
					<p class="body-text"><span class="keypoint_underline">A young patient with an unusual corneal contour who is considering refractive surgery (eg, LASIK, PRK) should be observed over time to determine the possibility of progression &#173;toward KC.</span></p>
					<p class="reference-first">Belin&#160;MW, Kundu&#160;G, Shetty&#160;N, Gupta&#160;K, Mullick&#160;R, Thakur&#160;P. ABCD: a new classification for keratoconus. <span class="reference_italic">Indian J&#160;Ophthalmol</span>. 2020;68(12):2831–2834.</p>
					<p class="reference-mid">Gomes&#160;JAP, Tan&#160;D, Rapuano&#160;CJ, et&#160;al; Group of Panelists for the Global Delphi Panel of Keratoconus and Ectatic Diseases. Global consensus on keratoconus and ectatic diseases. <span class="reference_italic">Cornea</span>. 2015;34(4):359–369.</p>
					<p class="reference-mid">Kuo&#160;AN, Cortina&#160;MS, Greiner&#160;MA, et&#160;al. Advanced corneal imaging in keratoconus: a report by the American Acad&#173;emy of Ophthalmology. <span class="reference_italic">Ophthalmology</span>. 2024;131(1):107–121.</p>
					<p class="reference-mid">Li&#160;Y, Chamberlain&#160;W, Tan&#160;O, Brass&#160;R, Weiss&#160;JL, Huang&#160;D. Subclinical keratoconus detection by pattern analy&#173;sis of corneal and epithelial thickness maps with optical coherence tomography. <span class="reference_italic">J Cataract Refract Surg</span>. 2016;42(2):284–295.</p>
					<p class="reference-mid">Perez-&#173;Straziota&#160;CE, Schallhorn&#160;JM. <span class="reference_italic">OCT epithelial mapping for refractive screening</span> [2017 American Acad&#173;emy of Ophthalmology Annual Meeting Video]. American Acad&#173;emy of Ophthalmology; 2017. <a target="_blank" href="http://aao.org">aao.org</a></p>
					<p class="reference-mid">Rojas&#160;MJ, Belin&#160;MW, Yeu&#160;E. Topographic analy&#173;sis in keratorefractive surgery. In: Mannis&#160;MJ, Holland&#160;EJ, eds. <span class="reference_italic">Surgery of the Cornea and Conjunctiva.</span> 5th&#160;ed. Elsevier; 2022:1674–1681. <span class="reference_italic">Cornea;</span> vol 2.</p>
					<p class="h2">Pathology</p>
					<p class="body-text--no-indent-">Histologic examination reveals the following characteristics of KC:</p>
					<ul>
						<li class="bullet-list-first">iron deposition in the basal epithelium at the base of the cone</li>
						<li class="bullet-list-mid">fragmentation or breaks in Bowman layer with fibrous growth</li>
						<li class="bullet-list-mid">thinning of the corneal stroma and overlying epithelium</li>
						<li class="bullet-list-mid">folds or breaks in Descemet membrane</li>
						<li class="bullet-list-mid">variable amounts of apical scarring</li>
					</ul>
					<p class="h2">Management</p>
					<p class="body-text--no-indent-">The first goal in the treatment of patients with KC is to stop disease progression. When &#173;there are signs of progression in refraction, CDVA, or tomography, corneal crosslinking can be performed barring any contraindications. When the KC is stable, the patient may be followed up. It is impor&#173;tant to counsel patients about the risk of disease progression with continued eye rubbing, which in turn can be reduced with optimal management of atopic diseases. As noted &#173;earlier, KC may pro&#173;gress rapidly in young patients (in their teens and twenties); thus, they should be examined more frequently. The disease is more likely to be stable in patients older than 40&#160;years, but progression can still occur.</p>
					<p class="body-text">A second goal in the treatment of patients with KC is to improve their vision. Mild KC can be successfully managed with glasses, although many patients require contact lenses to achieve good vision. Contact lenses can mask the associated irregular corneal astigmatism, and most affected patients report a dramatic improvement in vision with their use. In advanced cases of KC, however, scarring and contour distortion can reduce the contact lens–&#173;corrected vision and make it difficult to achieve a stable fit. In addition, contact lens wear does not prevent KC progression; therefore, patients in their teens and twenties should be followed up closely as mentioned &#173;earlier. Although most patients &#173;will require rigid gas-&#173;permeable (RGP) lenses or scleral lenses, some patients, particularly &#173;those with mild disease, may achieve improved vision and comfortable wear with soft lenses. Contact lens options include</p>
					<ul>
						<li class="bullet-list-first">soft toric lens</li>
						<li class="bullet-list-mid">RGP hard lens</li>
						<li class="bullet-list-mid">bicurved hard lens</li>
						<li class="bullet-list-mid">hybrid lens (hard center and soft skirt)</li>
						<li class="bullet-list-mid">additive lens system (piggyback) system (an RGP lens fitted over a soft lens)</li>
						<li class="bullet-list-last">scleral lens with high oxygen permeability (an increasingly &#173;popular option for patients unable to wear the standard RGP lens)</li>
					</ul>
					<p class="body-text"><span class="italic">Corneal hydrops</span> (see Fig&#160;9-7) is treated conservatively with topical hypertonic agents and/or a soft contact lens for several months &#173;after onset. A cycloplegic agent and topical &#173;steroid may provide short-&#173;term relief by reducing inflammation and pain, and aqueous suppressants may decrease the flow of fluid into the cornea. Intracameral injection of air or a nonexpansile concentration of gas (SF<span class="subscript _idGenCharOverride-1">6</span> or C<span class="subscript _idGenCharOverride-1">3</span>F<span class="subscript _idGenCharOverride-1">8</span>) may help accelerate the resolution of hydrops, and pupillary dilation and/or inferior peripheral iridectomy may reduce the risk of pupillary block &#173;after intracameral gas injection. Hydrops is not an indication for urgent keratoplasty.</p>
					<p class="reference-single ParaOverride-1">Bafna&#160;RK, Kalra&#160;N, Asif&#160;MI, et&#160;al. Management of acute corneal hydrops—&#173;current perspectives. <span class="italic">Indian J&#160;Ophthalmol.</span> 2024;72(4):495–507. <a target="_blank" href="https://doi.org/10.4103/IJO.IJO_2160_23">doi:10.4103/IJO.IJO_2160_23</a></p>
					<p class="h2 ParaOverride-7">Surgical Treatment Options</p>
					<p class="h3-h2">Corneal crosslinking</p>
					<p class="body-text--no-indent-">Corneal crosslinking (CXL) is the first-&#173;line treatment in patients who demonstrate progressive KC disease (including older patients) and &#173;those who are at significant risk of progression, particularly adolescents and &#173;those with a &#173;family history of KC. CXL is most effective in mild to moderate cases of KC and in cases of post-&#173;LASIK ectasia; results in patients with advanced KC are more variable. &#173;Because the goal of crosslinking is to stop disease progression, not to rehabilitate vision, patients should be counseled that they &#173;will still require glasses or contact lenses &#173;after the procedure.</p>
					<p class="h4-text ParaOverride-8"><span class="h4-head">Evaluation</span> &#173;There are no well-&#173;defined criteria for KC progression, but the proposed metrics for CXL evaluation are</p>
					<ul>
						<li class="bullet-list-first">mean and/or maximum keratometry values</li>
						<li class="bullet-list-mid">steepening of the anterior and posterior corneal surfaces</li>
						<li class="bullet-list-mid">thinnest pachymetry reading</li>
						<li class="bullet-list-mid">rate of change in thickness from the thinnest part of the cornea to the periphery</li>
						<li class="bullet-list-last">refractive astigmatism</li>
					</ul>
					<p class="body-text">CXL is relatively contraindicated in the following cases:</p>
					<ul>
						<li class="bullet-list-first">corneal thickness <span class="bullet-list_symbol">&lt;</span>400&#160;µm at the time of UVA treatment (hypotonic riboflavin drops may help increase thickness prior to UVA treatment), and some protocols may allow for treatment of thinner corneas (ie, riboflavin-&#173;soaked contact lens or reduced UVA dose)</li>
						<li class="bullet-list-mid">prior herpetic infection (due to possibility of viral reactivation with UVA irradiation)</li>
						<li class="bullet-list-mid">severe corneal scarring or opacification</li>
						<li class="bullet-list-mid">history of poor epithelial wound healing</li>
						<li class="bullet-list-mid">severe ocular surface disease (eg, dry eye)</li>
						<li class="bullet-list-mid">autoimmune disorders</li>
					</ul>
					<p class="h4-text"><span class="h4-head">Surgical technique</span> CXL involves the saturation of the cornea with topical riboflavin (vitamin B<span class="h4_subscript _idGenCharOverride-1">2</span>) solution, followed by exposure to UVA light at 365&#160;nm. Oxygen &#173;free radicals, generated by the combination of photosensitizer riboflavin, oxygen, and UVA light, induce crosslinking in the collagenous corneal tissue, thereby increasing its rigidity. Removal of the epithelium (ie, epithelium-&#173;off, or “epi-&#173;off”) facilitates the stromal impregnation of riboflavin.</p>
					<p class="body-text">In the presence of riboflavin, approximately 95% of the UVA light is absorbed in the anterior corneal stroma to a depth of 300&#160;µm. To avoid UVA-&#173;induced corneal endothelial damage, a minimal stromal thickness of 400&#160;µm &#173;after epithelial removal was recommended by Spoerl et&#160;al. Safety studies based on &#173;these thickness guidelines have shown that CXL does not damage the endothelium. In thinner corneas, a hypotonic riboflavin solution can be applied prior to UVA illumination to temporarily thicken the cornea. For additional UVA absorption in thin corneas, a &#173;bandage contact lens soaked with riboflavin can be applied during illumination. In addition, a protocol for thin corneas that shortens UVA treatment duration according to corneal thickness has shown efficacy and safety.</p>
					<p class="reference-first">Hafezi&#160;F, Kling&#160;S, Gilardoni&#160;F, et&#160;al. Individualized corneal cross-&#173;linking with riboflavin and UV-&#173;A in ultrathin corneas: the sub400 protocol. <span class="reference_italic">Am J&#160;Ophthalmol</span>. 2021;224:133–142.</p>
					<p class="reference-mid">Rubinfeld&#160;RS, Caruso&#160;C, Ostacolo&#160;C. Corneal cross-&#173;linking: the science beyond the myths and misconceptions. <span class="reference_italic">Cornea</span>. 2019;38(6):780–790.</p>
					<p class="reference-mid">Spoerl&#160;E, Mrochen&#160;M, Sliney&#160;D, Trokel&#160;S, Seiler&#160;T. Safety of UVA-&#173;riboflavin cross-&#173;linking of the cornea. <span class="reference_italic">Cornea.</span> 2007;26(4):385–389.</p>
					<p class="h5-text"><span class="h5-head">dresden protocol</span> Although crosslinking has been used globally for 2 &#173;decades, epi-&#173;off CXL was not approved by the US Food and Drug Administration (FDA) &#173;until 2016 for patients aged 14–65&#160;years with progressive KC or postrefractive surgery ectasia. The FDA-&#173;approved technique for CXL (termed the <span class="h5-text_italic">Dresden protoco</span><span class="h5-text_italic">l</span>) is as follows:</p>
					<ul>
						<li class="bullet-list-first">The central corneal epithelium (9&#160;mm) is removed.</li>
						<li class="bullet-list-mid">Topical riboflavin (0.1% diluted in 20% dextran) is instilled &#173;every 2 minutes for 30 minutes.</li>
						<li class="bullet-list-mid">The slit lamp is used to check riboflavin fluorescence in the anterior chamber of the eye.</li>
						<li class="bullet-list-mid">Corneal thickness is checked with ultrasonic pachymetry. If the exposed stroma is less than 400&#160;µm, a hypotonic riboflavin solution is applied &#173;every 15 seconds for 2 minutes &#173;until the &#173;measurement is <span class="bullet-list_symbol">≥</span>400&#160;µm.</li>
						<li class="bullet-list-mid">This is followed by a 30-&#173;minute UVA treatment (365&#160;nm: 3 mW/cm<span class="bullet-list_superscript _idGenCharOverride-1">2</span> irradiation) with concomitant application of topical riboflavin &#173;every 2 minutes (<span class="bullet-list_xref-figure xref-figure" id="Fig 9-11">Fig&#160;9-11</span>).</li>
						<li class="bullet-list-last">At the conclusion of the procedure, the riboflavin is washed out, and a &#173;bandage contact lens is placed.</li>
					</ul>
					<p class="body-text">&#173;Because the CXL procedure using the Dresden protocol takes more than 60 minutes and requires epithelial removal, accelerated protocols and techniques that enable transepithelial impregnation of riboflavin (epithelium-on, or “epi-on”) are being evaluated. &#173;These techniques, which increase epithelial permeability or use modified riboflavin solutions to facilitate penetration, may enhance patient safety as well as shorten the procedure.</p>
					<p class="h4-text"><span class="h4-head">Combined techniques</span> Although the goal of CXL is to stop progression of KC, ophthalmologists have attempted to combine crosslinking with vari&#173;ous refractive surgical techniques to improve visual acuity. For example, the implantation of intrastromal corneal ring segments (see the subsection “Intrastromal corneal ring segments”) with sequential or subsequent CXL treatment may be efficacious. Studies have shown that the &#173;limited use of topography-&#173;guided transepithelial PRK followed by CXL can improve visual acuity and stabilize KC. Before surgery, it is impor&#173;tant to counsel patients regarding the risk of progressive ectasia &#173;after PRK.</p>
					<p class="reference-first">D’Oria&#160;F, Bagaglia&#160;SA, Alio Del Barrio&#160;JL, Alessio&#160;G, Alio&#160;JL, Mazzotta&#160;C. Refractive surgical correction and treatment of keratoconus. <span class="reference_italic">Surv Ophthalmol</span>. 2024;69(1):122–139.</p>
					<p class="reference-mid">Grentzelos&#160;MA, Liakopoulos&#160;DA, Kankariya&#160;VP, et&#160;al. Three-&#173;year results of simultaneous transepithelial phototherapeutic keratectomy and conventional photorefractive keratectomy (Cretan Protocol Plus) followed by corneal crosslinking for keratoconus. <span class="reference_italic">Cornea</span>. 2023;42(6):680–686.</p>
					<p class="reference-mid">Zaky&#160;AG, KhalafAllah MT, Sarhan&#160;AE. Combined corneal cross-&#173;linking and 320° intrastromal corneal ring segments in progressive keratoconus: one-&#173;year results. <span class="reference_italic">Graefe’s Arch Clin Exp Ophthalmol</span>. 2020;258(11):2441–2447.</p>
					<p class="h4-text"><span class="h4-head">Outcomes</span> Long-&#173;term studies have confirmed that CXL stops the progression of KC. A meta-&#173;analysis of 75 publications with follow-up periods exceeding 36 months showed a greater improvement in uncorrected distance visual acuity than CDVA, along with a reduction in keratometric (corneal topography) values. Although a minor reduction in astigmatism was observed, &#173;there was no change in the &#173;spherical equivalent. A longer-&#173;term study (with a follow-up period of 15&#160;years &#173;after CXL) demonstrated a significant decrease in the maximum and mean keratometry values and astigmatism. CDVA also improved significantly. Keratometry values, corneal thickness, and visual acuity did not change between 10 and 15&#160;years, indicating stabilization of the keratoconic cornea. Nevertheless, re-&#173;treatment was needed in 14% of cases.</p>
					<p class="body-text">The phase 3 multicenter US study that supported the FDA approval of CXL for progressive KC and corneal ectasia compared eyes treated with the Dresden CXL protocol with sham control eyes and demonstrated reduction of keratometry values and improvement in CDVA in the treatment group.</p>
					<p class="body-text">Another ongoing phase 3, prospective, multicenter US study is comparing the safety and efficacy of epi-on CXL with placebo in reducing maximal topographic keratom&#173;etry values (Kmax) in keratoconic eyes. Positive results may prompt FDA approval for an &#173;epi-on CXL treatment that &#173;will eliminate the need for epithelial removal and its complications. Fi&#173;nally, international studies have found a reduction in corneal transplantations for KC since the introduction of CXL.</p>
					<p class="body-text">As stated &#173;earlier, patients with mild to moderate KC have a better prognosis &#173;after CXL than patients with more severe disease. &#173;Because the disease tends to pro&#173;gress more rapidly in young patients than in older patients, more frequent examinations are required to detect progression and intervene with CXL. Patients with post-&#173;LASIK ectasia may not do as well as patients with KC, perhaps &#173;because the flap provides less biomechanical stability than an untreated cornea.</p>
					<p class="reference-first">Borchert&#160;GA, Kandel&#160;H, Watson&#160;SL. Epithelium-on versus epithelium-&#173;off corneal collagen crosslinking for keratoconus: a systematic review and meta-&#173;analysis. <span class="reference_italic">Graefe’s Arch Clin Exp Ophthalmol</span>. 2024;262(6):1683–1692.</p>
					<p class="reference-mid">Hagem&#160;AM, Thorsrud&#160;A, S<span class="reference_accent">æ</span>thre M, Sandvik&#160;G, Kristianslund&#160;O, Drolsum&#160;L. Dramatic reduction in corneal transplants for keratoconus 15&#160;years &#173;after the introduction of corneal collagen crosslinking. <span class="reference_italic">Cornea</span>. 2024;43(4):437–442.</p>
					<p class="reference-mid">Hersh&#160;PS, Stulting&#160;RD, Muller&#160;D, Durrie&#160;DS, Rajpal RK; United States Crosslinking Study Group. United States multicenter clinical trial of corneal collagen crosslinking for keratoconus treatment. <span class="reference_italic">Ophthalmology</span>. 2017;124(9):1259–1270.</p>
					<p class="reference-mid">Hersh&#160;PS, Stulting&#160;RD, Muller&#160;D, Durrie&#160;DS, Rajpal RK; U.S. Crosslinking Study Group. U.S. multicenter clinical trial of corneal collagen crosslinking for treatment of corneal ectasia &#173;after refractive surgery. <span class="reference_italic">Ophthalmology.</span> 2017;124(10):1475–1484.</p>
					<p class="reference-mid">Kandel&#160;H, Abbondanza&#160;M, Gupta&#160;A, et&#160;al. Comparison of standard versus accelerated corneal collagen cross-&#173;linking for keratoconus: 5-&#173;year outcomes from the Save Sight Keratoconus Registry. <span class="reference_italic">Eye (Lond)</span>. 2024;38(1):95–102.</p>
					<p class="reference-mid">Raiskup&#160;F, Herber&#160;R, Lenk&#160;J, et&#160;al. Corneal crosslinking with riboflavin and UVA light in progressive keratoconus: fifteen-&#173;year results. <span class="reference_italic">Am J&#160;Ophthalmol</span>. 2023;250:95–102.</p>
					<p class="h4-text"><span class="h4-head">Complications</span> Pos&#173;si&#173;ble complications of CXL include</p>
					<ul>
						<li class="bullet-list-first">photophobia</li>
						<li class="bullet-list-mid">delayed epithelial healing (in epi-&#173;off treatments)</li>
						<li class="bullet-list-mid">corneal stromal haze (<span class="xref-figure" id="Fig 9-12">Fig&#160;9-12</span>), which may be visually significant</li>
						<li class="bullet-list-mid">decreased corneal sensitivity</li>
						<li class="bullet-list-mid">infectious keratitis</li>
						<li class="bullet-list-mid">sterile infiltrates</li>
						<li class="bullet-list-mid">corneal melting</li>
						<li class="bullet-list-last">per&#173;sis&#173;tent corneal edema due to endothelial cell damage</li>
					</ul>
					<p class="body-text"><span class="xref-table" id="Table 9-2">&#173;Table&#160;9-2</span> pre&#173;sents the incidence of complications related to epi-&#173;off CXL. Complications seem to occur more frequently in patients older than 35&#160;years and &#173;those with preoperative maximum steepening greater than 58.00 D.</p>
					<p class="reference-first">Koller&#160;T, Mrochen&#160;M, Seiler&#160;T. Complication and failure rates &#173;after corneal crosslinking. <br /><span class="reference_Hyperlink_italic">J Cataract Refract Surg.</span> 2009;35(8):1358–1362.</p>
					<p class="h3">Additional surgical options for keratoconus</p>
					<p class="h4-text ParaOverride-9"><span class="h4-head">Keratectomy</span> Apical subepithelial scarring due to advanced keratoconus is a common cause of contact lens intolerance. It can be scraped mechanically using a blade (keratectomy) or removed by phototherapeutic keratectomy. Depth of the scarring can be assessed by slit-&#173;lamp examination or anterior segment OCT to determine the safety of its removal. Figure&#160;9-6 shows a superficial apical scar that was treated before cataract surgery to enable corneal biometry &#173;measurements. Treatment can improve patient comfort and vision, but scarring may recur.</p>
					<p class="h4-text"><span class="h4-head">Intrastromal corneal ring segments</span> Intrastromal corneal ring segments (ICRSs) are circular arcs made of polymethyl methacrylate that are surgically implanted in the posterior midperipheral corneal stroma (<span class="h4-text_xref-figure xref-figure" id="Fig 9-13">Fig&#160;9-13</span>). The rings can center the cone and may facilitate successful contact lens wear. They are implanted through lamellar channels that can be created using a blunt dissector mounted on a suction ring or by a femtosecond &#173;laser (Video&#160;9-3); this procedure is sometimes performed in combination with CXL. Placement of ICRSs does not prevent KC progression and is not intended to reduce dependence on glasses or contact lenses. In addition, the rings can migrate or extrude. Corneal thinning over ring segments (<span class="xref-figure" id="Fig 9-14">Fig&#160;9-14A</span>) can also lead to epithelial defects (Fig&#160;9-14B) or microbial keratitis and may require ring explantation.</p>
					<p class="QR-code-caption-first"><span class="QR-code-number">VIDEO&#160;9-3</span> Implantation of asymmetric corneal ring segments in <br />keratoconus.</p>
					<!--<div class="_idGenObjectLayout-1">
						<div id="_idContainer010" class="video-r _idGenObjectStyleOverride-1">
							<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/bcsc-2025-26-video-icon-interior2.jpg" alt="" />
						</div>
					</div>-->
					<div class="_idGenObjectLayout-1">
						<div id="_idContainer011" class="video-r _idGenObjectStyleOverride-1">
							<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/qr-BCSC25_S08_09-03.jpg" alt="" />
						</div>
					</div>
					<p class="QR-code-source ParaOverride-1"><span class="qr-code-source_italic">Courtesy of George&#160;O.&#160;Waring&#160;IV, MD.</span></p>
					<p class="QR-code-source-left">Available at: <a target="_blank" href="http://aao.org/bcscvideo_section08">aao.&#173;org/&#173;bcscvideo_&#173;section08</a></p>
					<p class="reference-mid">D’Oria&#160;F, Abdelghany&#160;AA, Ledo&#160;N, Barraquer&#160;RI, Alio&#160;JL. Incidence and reason for intrastromal corneal ring segment explantation. <span class="reference_italic">Am J&#160;Ophthalmol</span>. 2021;222:351–358.</p>
					<p class="h4-text"><span class="h4-head">Keratoplasty</span> Penetrating keratoplasty (PK; also abbreviated as PKP) and deep anterior lamellar keratoplasty (DALK) are currently the preferred cornea transplant procedures for the treatment of KC in the United States and are associated with an excellent prognosis. Although DALK is technically more challenging, it has several advantages over PK. For example, at 6 months &#173;after DALK, endothelial cell counts are significantly higher than they are with PK. In addition, endothelial rejection does not occur with DALK, although stromal rejection is still pos&#173;si&#173;ble. Stromal scarring can also result in reduced vision and symptoms of glare. See <span class="h4-text_xref-local">Chapter&#160;16</span> for further discussion of PK (Video&#160;16-1) and DALK (Video&#160;16-3).</p>
					<p class="body-text"><span class="italic">Keratoplasty</span> becomes an impor&#173;tant option &#173;under the following circumstances:</p>
					<ul>
						<li class="bullet-list-first">poor vision even with a comfortable, stable-&#173;fitting contact lens (usually due to scarring or irregular astigmatism)</li>
						<li class="bullet-list-mid">contact lens intolerance despite the good vision achieved with the lens</li>
						<li class="bullet-list-mid">unstable contact lens fit (even with good vision and lens tolerance)</li>
						<li class="bullet-list-mid">progressive thinning &#173;toward the corneal periphery approaching the limbus, which requires a very large graft (associated with increased risk of rejection)</li>
						<li class="bullet-list-mid">corneal hydrops that fails to clear &#173;after several months</li>
					</ul>
				</div>
			
			<p class="h1">Pellucid Marginal Degeneration</p>
				<div id="Chapt9_Top3">
					<p class="body-text--no-indent-">Pellucid marginal degeneration (PMD) is an uncommon, usually nonhereditary, and bilateral corneal disorder with an unknown etiology. It is associated with peripheral corneal thinning without inflammation. PMD and KC can occur in members of the same &#173;family. In rare instances, both diseases may be pre&#173;sent in the same eye. PMD may be part of an ectasia continuum that includes KC (Case Study 9-1).</p>
					<!--<div class="_idGenObjectLayout-1">
						<div id="_idContainer012" class="video-icon _idGenObjectStyleOverride-1">
							<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/bcsc-2025-26-case-study-icon-interior.jpg" alt="" />
						</div>
					</div>-->
					<p class="QR-code-caption-first_right"><span class="QR-code-number">CASE STUDY 9-1</span> Corneal ectasia.</p>
					<div class="_idGenObjectLayout-1">
						<div id="_idContainer013" class="video-r _idGenObjectStyleOverride-1">
							<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/qr-BCSC25_S08_09_01_Case.jpg" alt="" />
						</div>
					</div>
					<p class="QR-code-source_right"><span class="qr-code-source_italic">Courtesy of Robert&#160;S.&#160;Feder, MD.</span></p>
					<p class="QR-code-source_right ParaOverride-4">
						<!--<span class="CharOverride-1">Available at: </span>-->
						<span>Available at: </span>
						<a target="_blank" href="http://aao.org/bcsccasestudy_section08">
							<!--<span class="CharOverride-1">aao.&#173;org/&#173;bcsccasestudy_&#173;section08</span>-->
							<span>aao.&#173;org/&#173;bcsccasestudy_&#173;section08</span>
						</a>
					</p>
					<p class="h5-text ParaOverride-9"><span class="h5-head">clinical &#173;presentation</span> PMD is diagnosed in patients aged 20<span class="h5-text_figuredash">‒</span>40&#160;years and affects men and &#173;women equally. The high, irregular astigmatism characteristic of PMD &#173;causes decreased vision. <span class="keypoint_underline">In patients with PMD, a 1–2-mm wide band of inferior corneal thinning (
					<span class="xref-figure" id="Fig 9-2"></span>
					<span class="xref-figure" id="Fig 9-15">Fig&#160;9-15</span>
					), which occurs 1–2&#160;mm from the limbus and extends up to 4 clock-&#173;hours (usually 4–8 &#173;o’clock), is typically observed.</span> In rare cases, PMD may occur in the superior cornea.</p>
					<div class="_idGenObjectLayout-1">
						<div id="_idContainer014" class="keypoint-l">
							<!--<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/bcsc-2025-26-keypoint-icon-interior.jpg" alt="" />-->
						</div>
					</div>
					<p class="body-text">&#173;There are some marked differences between PMD and KC.&#160;In&#160;PMD, corneal protrusion occurs at the central edge of the thinned area (<span class="xref-figure" id="Fig 9-16">Fig&#160;9-16</span>), resulting in a contour resembling a “beer belly.” In contrast, the keratoconic cornea protrudes at the point of maximal thinning, which is typically just below the center (see Fig&#160;9-2). At times, however, a clear distinction between PMD and KC is not pos&#173;si&#173;ble. For example, although the “crab claw” pattern is characteristic of the tomographic map of PMD (<span class="xref-figure" id="Fig 9-17">Fig&#160;9-17</span>), a similar configuration can be found in inferior KC as well. Clinical correlation and review of elevation and pachymetric maps provide more accurate differentiation between &#173;these 2 disorders.</p>
					<p class="body-text">PMD is not associated with vascularization or lipid deposition, but posterior stromal scarring has been noted in the thinned area. &#173;These observations help differentiate PMD from other peripheral thinning disorders (<span class="xref-table" id="Table 9-3">&#173;Table&#160;9-3</span>). In addition, studies have reported the occurrence of acute corneal hydrops, as well as rare, spontaneous corneal perforation with PMD.</p>
					<p class="h5-text"><span class="h5-head">pathology</span> Pathologic examination reveals the following characteristics of PMD:</p>
					<ul>
						<li class="bullet-list-first">normal-&#173;appearing epithelium, Descemet membrane, and endothelium</li>
						<li class="bullet-list-mid">stromal thinning with focal disruption of Bowman layer</li>
						<li class="bullet-list-mid">absence of lipid deposits; &#173;these deposits are typical of Terrien marginal degeneration</li>
					</ul>
					<p class="h5-text"><span class="h5-head">management</span> Early-&#173;stage PMD is treated with contact lenses, although the fit is more difficult to achieve in PMD than in KC. Scleral lenses are more commonly used in the treatment of PMD, although hybrid lenses are occasionally prescribed. Eventually, PK or DALK may be required to restore vision. Due to the location of the corneal thinning, the grafts tend to be large and close to the limbus, making surgery technically more difficult and the graft more prone to rejection. Wedge resection and lamellar grafts are advocated as alternative or adjunctive procedures. Corneal crosslinking may also be considered for some of &#173;these patients.</p>
					<p class="reference-first">Belin&#160;MW, Asota&#160;IM, Ambrosio R&#160;Jr, Khachikian&#160;SS.&#160;What’s in a name: keratoconus, pellucid marginal degeneration, and related thinning disorders. <span class="reference_italic">Am J&#160;Ophthalmol.</span> 2011;152(2):157–162.e1.</p>
					<p class="reference-mid">Belin&#160;MW, Boyd&#160;BM, Ambrosio R&#160;Jr. Pellucid marginal degeneration vs inferior keratoconus: why it &#173;matters. <span class="reference_italic">J Cataract Refract Surg.</span> 2020;46(2):325–326.</p>
					<p class="reference-mid">Pircher&#160;N, Lammer&#160;J, Holzer&#160;S, Gschliesser&#160;A, Schmidinger&#160;G. Corneal crosslinking for pellucid marginal degeneration. <span class="reference_italic">J Cataract Refract Surg.</span> 2019;45(8):1163–1167.</p>
				</div>
			
			<p class="h1">Keratoglobus</p>
				<div id="Chapt9_Top1">
					<p class="body-text--no-indent-">Keratoglobus is a rare, bilateral, noninflammatory condition that is typically pre&#173;sent at birth, unlike KC and PMD. It is usually not inherited.</p>
					<p class="h5-text"><span class="h5-head">clinical &#173;presentation</span> Keratoglobus can be confused with other conditions in the differential diagnosis. In patients with keratoglobus, the corneas have a globular shape (see Fig 9-18C) with a deep anterior chamber and a normal dia&#173;meter. <span class="keypoint_underline">Patients generally pre&#173;sent with diffuse corneal steepening and diffuse thinning that is worse in the periphery (
					<span class="xref-figure" id="Fig 9-2"></span>
					<span class="xref-figure" id="Fig 9-18">Figs&#160;9-18</span>, 
					<span class="xref-figure" id="Fig 9-19">9-19</span>, 
					<span class="xref-table" id="Table 9-4">Table 9-4</span>
					).</span> This is in contrast to KC, which pre&#173;sents with inferior paracentral thinning at the cone apex (see Fig&#160;9-2). In patients with keratoglobus, spontaneous rupture of Descemet membrane with corneal hydrops can occur, but iron lines, stress lines, and anterior scarring are not typically seen. Prominent folds with focal areas of thickening in Descemet membrane are common. Also unlike KC, keratoglobus is not associated with atopy. Keratoglobus is strongly associated with blue sclerae and Ehlers-&#173;Danlos syndrome type VI (see <span class="h5-text_xref-local">Chapter&#160;10</span>).</p>
					<div class="_idGenObjectLayout-1">
						<div id="_idContainer015" class="keypoint-l">
							<!--<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/bcsc-2025-26-keypoint-icon-interior.jpg" alt="" />-->
						</div>
					</div>
					<p class="h5-text"><span class="h5-head">pathology</span> Keratoglobus may represent a defect in collagen synthesis. Histologic examination reveals the following characteristics:</p>
					<ul>
						<li class="bullet-list-first">absent or fragmented Bowman layer</li>
						<li class="bullet-list-mid">thinned stroma with normal lamellar &#173;organization</li>
						<li class="bullet-list-mid">thin Descemet membrane</li>
					</ul>
					<p class="h5-text"><span class="h5-head">management</span> Contact lenses, especially scleral lenses, may be beneficial for managing keratoglobus. The prognosis for PK is much poorer in keratoglobus than in the other corneal ectasias. In cases requiring intervention to maintain functional vision, lamellar keratoplasty, followed by PK, may be considered. Due to the possibility of spontaneous corneal rupture, patients must be counseled regarding the importance of protective eyewear. In &#173;children, high myopia is treated with glasses to prevent amblyopia.</p>
					<p class="reference-first">Wallang&#160;BS, Das&#160;S.&#160;Keratoglobus. <span class="reference_italic">Eye (Lond).</span> 2013;27(9):1004–1012.</p>
				</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-1">
			<div id="_idContainer019">
				<div id="_idContainer018" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-5" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-01.jpg" alt="" />
				</div>
				<div id="_idContainer017" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-1</span> Clinical photo&#173;graph of keratoconus. Note the marked corneal protrusion, which is a hallmark of keratoconus. <span class="figure-source-note">(Courtesy of Arie&#160;L.&#160;Marco&#173;vich, MD, PhD.)</span></p>
				</div>
			</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-2">
			<div id="_idContainer022">
				<div id="_idContainer021" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-02.jpg" alt="" />
				</div>
				<div id="_idContainer020" class="cap">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-2</span> Illustration showing the outline of the cornea in a healthy eye and of the corneal thinning in dif&#173;fer&#173;ent ectatic disorders. <span class="figure-caption_bold">A,</span> Normal cornea. <span class="figure-caption_bold">B,</span> Keratoconus: a cone-&#173;shaped thinning occurs, typically below the center. <span class="figure-caption_bold">C,</span> Pellucid marginal degeneration: corneal protrusion occurs at the central edge of a band-&#173;shaped inferior peripheral corneal thinning, resulting in a “beer-&#173;belly” contour. <span class="figure-caption_bold">D,</span> Keratoglobus: diffuse corneal steepening and thinning that is worse in the periphery. <span class="figure-source-note">(Courtesy of Arie&#160;L.&#160;Marcovich, MD, PhD, and Mor Schlesinger, MD.)</span></p>
				</div>
			</div>
		</div>
		
		<!--Image cut half-->
		<div class="_idGenObjectLayout-1" id="Fig 9-3">
			<div id="_idContainer024" class="_idGenObjectStyleOverride-1">
				<!--<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-03-4.jpg" alt="" />-->
				<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-03.jpg" alt="" />
			</div>
			<div id="_idContainer025" class="Basic-Text-Frame">
				<p class="figure-caption"><span class="figure-number">Figure&#160;9-3</span> Clinical photo&#173;graph of Munson sign. Note the angulation of the lower eyelid with the eye in downgaze. <span class="figure-source-note">(Courtesy of Woodford&#160;S.&#160;Van Meter, MD.)</span></p>
			</div>
		</div>
			
		<!--Image cut half-->
		<div class="_idGenObjectLayout-1" id="Fig 9-4">
			<div id="_idContainer024" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-04.jpg" alt="" />
			</div>
			<div id="_idContainer026" class="Basic-Text-Frame">
				<p class="figure-caption"><span class="figure-number">Figure&#160;9-4</span> Fleischer ring <span class="figure-caption_italic">(arrows),</span> iron deposited at the base of the cone, is best seen with the slit lamp using a broad, oblique beam. Vogt striae, fine folds in the posterior stroma, are seen at the apex of the cone <span class="figure-caption_italic">(arrowhead).</span> <span class="figure-source-note">(Courtesy of Arie&#160;L.&#160;Marcovich, MD, PhD.)</span></p>
			</div>
		</div>
		
		<!--<div class="_idGenObjectLayout-1" id="Fig 9-4">
			<div id="_idContainer024" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-03-4.jpg" alt="" />
			</div>
			
		</div>-->
		
		<!--Image cut half-->
		<div class="_idGenObjectLayout-1" id="Fig 9-5">
			<div id="_idContainer030">
				<div id="_idContainer027" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-05.jpg" alt="" />
				</div>
				<div id="_idContainer028" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-5</span> Slit-&#173;lamp image of a reticular apical scar <span class="figure-caption_italic">(arrow).</span> The slit beam demonstrates the extreme corneal thinning at the cone apex. <span class="figure-source-note">(Courtesy of Arie&#160;L.&#160;Marcovich, MD, PhD.)</span></p>
				</div>
			</div>
		</div>
			
		<!--Image cut half-->
		<div class="_idGenObjectLayout-1" id="Fig 9-6">
			<div id="_idContainer030">
				<div id="_idContainer027" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-06.jpg" alt="" />
				</div>
				<div id="_idContainer029" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-6</span> Slit-&#173;lamp image of a nummular scar at the apex of the cone related to contact lens wear <span class="figure-caption_italic">(arrow).</span> Scar depth can be evaluated by slit-&#173;beam examination or by anterior segment optical coherence tomography (OCT). The scar was removed using a blade before cataract surgery to enable corneal biometry &#173;measurements. <span class="figure-source-note">(Courtesy of Arie&#160;L.&#160;Marcovich, MD, PhD.)</span></p>
				</div>
			</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-7">
			<div id="_idContainer033">			
				<div id="_idContainer032" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-6" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-07.jpg" alt="" />
				</div>
				<div id="_idContainer031" class="cap">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-7</span> Clinical photo&#173;graph of acute hydrops. Acute hydrops is the sudden onset of corneal edema that results from rupture of Descemet membrane. Intrastromal and subepithelial fluid can also be seen. <span class="figure-source-note">(Courtesy of Arie&#160;L.&#160;Marcovich, MD, PhD.)</span></p>
				</div>
			</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-8">
			<div id="_idContainer034" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-08.jpg" alt="" />
			</div>
			<div id="_idContainer035" class="cap">
				<p class="figure-caption"><span class="figure-number">Figure&#160;9-8</span> Scheimpflug-&#173;based corneal contour map. <span class="figure-caption_italic">Upper left,</span> Power map with inferior steepening and superior flattening. <span class="figure-caption_italic">Upper right,</span> An isolated island of anterior elevation above a best-&#173;fit sphere coincident with the maximum steepness. <span class="figure-caption_italic">Lower right,</span> An isolated island of posterior elevation. <span class="figure-caption_italic">Lower left,</span> Marked thinning in an area coincident with maximum steepening and elevation. <span class="figure-source-note">(Courtesy of Robert&#160;S.&#160;Feder, MD.)</span></p>
			</div>
		</div>
				
		<div class="_idGenObjectLayout-1" id="Fig 9-9">
			<div id="_idContainer037" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-09.jpg" alt="" />
			</div>
			<div id="_idContainer036" class="cap">
				<p class="figure-caption"><span class="figure-number">Figure&#160;9-9</span> Anterior segment OCT of the left eye of a patient with keratoconus. <span class="figure-caption_bold">A:</span> <span class="figure-caption_italic">Upper left,</span> Power map with inferior steepening and superior flattening. Inferior-&#173;superior (I-&#173;S) ratio is 1.4 (I-S <span class="figure-caption_symbol">&gt;</span>1.2 is considered significant). <span class="figure-caption_italic">Upper right,</span> Inferior temporal anterior elevation above a best-&#173;fit sphere. <span class="figure-caption_italic">Lower right,</span> An isolated island of posterior elevation. <span class="figure-caption_italic">Lower left,</span> Marked thinning in an area coincident with maximum steepening and anterior and posterior elevation. <span class="figure-caption_bold">B:</span> <span class="figure-caption_italic">Left,</span> Epithelial map demonstrating inferior temporal thinning at the apex of the cone. <span class="figure-caption_italic">Right,</span> Coincident inferior temporal stromal thinning. <span class="figure-source-note">(Courtesy of Arie&#160;L.&#160;Marcovich, MD, PhD.)</span></p>
			</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-10">
			<div id="_idContainer040">
				<div id="_idContainer038" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-5" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-10.jpg" alt="" />
				</div>
				<div id="_idContainer039" class="cap">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-10</span> Anterior segment OCT of the right eye of the same patient imaged in Figure&#160;9-9 demonstrating an early-&#173;stage keratoconus. <span class="figure-caption_italic">Upper left,</span> An asymmetric bow-&#173;tie pattern with inferior steepening. <span class="figure-caption_italic">Lower left,</span> A pachymetric map decentered inferotemporally depicting normal corneal thickness. <span class="figure-caption_italic">Upper right,</span> Astigmatism without abnormal elevation. <span class="figure-caption_italic">Lower right,</span> Mild abnormal inferior temporal posterior elevation coincident with the area of maximal thinning. <span class="figure-source-note">(Courtesy of Arie&#160;L.&#160;Marcovich, MD, PhD.)</span></p>
				</div>
			</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-11">
			<div id="_idContainer044">
				<div id="_idContainer042" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-11.jpg" alt="" />
				</div>
				<div id="_idContainer043" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-11</span> Corneal crosslinking. Radial red lines <span class="figure-caption_italic">(arrow)</span> help the surgeon to adjust the distance between the UVA source and the eye. The green area <span class="figure-caption_italic">(arrowhead)</span> is the 9-mm irradiation zone. <span class="figure-source-note">(Courtesy of Robert&#160;S.&#160;Feder, MD.)</span></p>
				</div>
			</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-12">
			<div id="_idContainer047">
				<div id="_idContainer045" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-12.jpg" alt="" />
				</div>
				<div id="_idContainer046" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-12</span> Slit-&#173;lamp image shows corneal haze following crosslinking treatment <span class="figure-caption_italic">(arrow).</span> A Fleischer ring can also be seen <span class="figure-caption_italic">(arrowhead).</span> <span class="figure-source-note">(Courtesy of Arie&#160;L.&#160;Marcovich, MD, PhD.)</span></p>
				</div>
			</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-13">
			<div id="_idContainer051">
				<div id="_idContainer050" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-5" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-13.jpg" alt="" />
				</div>
				<div id="_idContainer049" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-13</span> Slit-&#173;lamp image shows 2 intrastromal ring segments implanted in the posterior midperipheral corneal stroma. <span class="figure-source-note">(Courtesy of Arie&#160;L.&#160;Marcovich, MD, PhD.)</span></p>
				</div>
			</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-14">
			<div id="_idContainer054">
				<div id="_idContainer053" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-14.jpg" alt="" />
				</div>
				<div id="_idContainer052" class="cap">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-14</span> <span class="figure-caption_bold">A,</span> Slit-&#173;lamp image shows corneal thinning over ring segments <span class="figure-caption_italic">(arrows).</span> <span class="figure-caption_bold">B,</span> Fluorescein staining demonstrates epithelial defects <span class="figure-caption_italic">(arrows)</span>. <span class="figure-source-note">(Courtesy of Arie&#160;L.&#160;Marcovich, MD, PhD.)</span></p>
				</div>
			</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-15">
			<div id="_idContainer058">
				<div id="_idContainer055" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-15.jpg" alt="" />
				</div>
				<div id="_idContainer056" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-15</span> Clinical photo&#173;graph of pellucid marginal degeneration. The condition is characterized by inferior corneal protrusion above the band of thinning, which occurs 1–2&#160;mm from the limbus and extends up to 4 clock-&#173;hours. <span class="figure-source-note">(Courtesy of Vincent&#160;P. deLuise, MD.)</span></p>
				</div>
			</div>
		</div>
	
		<div class="_idGenObjectLayout-1" id="Fig 9-16">
			<div id="_idContainer058">
				<div id="_idContainer055" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-16.jpg" alt="" />
				</div>
				<div id="_idContainer057" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-16</span> Slit-&#173;lamp photo&#173;graph demonstrating corneal protrusion above a band of stromal thinning in pellucid marginal degeneration. <span class="figure-source-note">(Cou</span><span class="figure-source-note">r</span><span class="figure-source-note">tesy of Arie&#160;L.&#160;Marcovich, MD, PhD.)</span></p>
				</div>
			</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-17">
			<div id="_idContainer059" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-5" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-17.jpg" alt="" />
			</div>
			<div id="_idContainer060" class="cap">
				<p class="figure-caption"><span class="figure-number">Figure&#160;9-17</span> Scheimpflug-&#173;based corneal images of pellucid marginal degeneration. <span class="figure-caption_italic">Upper left,</span> Axial curvature (front) shows the typical “crab claw” pattern of inferior peripheral steepening seen in pellucid marginal degeneration, which is also observed in keratoconus with an inferiorly located apex. <span class="figure-caption_italic">Upper right,</span> Area of anterior elevation coincident with the inferior peripheral steepening. <span class="figure-caption_italic">Lower left,</span> Abnormal inferior peripheral posterior elevation coincident with the area of maximal thinning. <span class="figure-caption_italic">Lower right,</span> A decentered pachymetric map indicating abnormal inferior corneal thinning. <span class="figure-source-note">(Courtesy of David Zadok, MD.)</span></p>
			</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-18">
			<div id="_idContainer063" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-18.jpg" alt="" />
			</div>
			<div id="_idContainer062" class="cap">
				<p class="figure-caption"><span class="figure-number">Figure&#160;9-18</span> Clinical photo&#173;graphs of keratoglobus, showing diffuse corneal thinning <span class="figure-caption_bold">(A),</span> blue sclera <span class="figure-caption_bold">(B),</span> and a globular cornea with marked peripheral thinning <span class="figure-caption_bold">(C).</span> <span class="figure-source-note">(Parts&#160;A and B courtesy of Arie&#160;L.&#160;Marcovich, MD, PhD; part&#160;C courtesy of Robert&#160;S.&#160;Feder, MD.)</span></p>
			</div>
		</div>
		
		<div class="_idGenObjectLayout-1" id="Fig 9-19">
			<div id="_idContainer066">
				<div id="_idContainer065" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-4" src="BCSC2025-26_S08_C09_p213_236_4P-web-resources/image/Figure_09-19.jpg" alt="" />
				</div>
				<div id="_idContainer064" class="cap">
					<p class="figure-caption"><span class="figure-number">Figure&#160;9-19</span> Keratoglobus. <span class="figure-caption_bold">A,</span> Scheimpflug-&#173;based power maps demonstrate marked diffuse corneal steepening <span class="figure-caption_italic">(top);</span> marked thinning and protrusion are seen in the Scheimpflug image <span class="figure-caption_italic">(bottom).</span> <span class="figure-caption_bold">B,</span> Thickness map shows marked thinning in a wide area. The dots indicate areas of poor reliability. <span class="figure-source-note">(Courtesy of Robert&#160;S.&#160;Feder, MD.)</span></p>
				</div>
			</div>
		</div>
		
		<div id="Table 9-1">
			<div id="_idContainer023" class="Basic-Text-Frame">
				<table id="table001" class="Basic-Table">
					<colgroup>
						<col class="_idGenTableRowColumn-1" />
						<col class="_idGenTableRowColumn-2" />
						<col class="_idGenTableRowColumn-3" />
						<col class="_idGenTableRowColumn-4" />
						<col class="_idGenTableRowColumn-1" />
					</colgroup>
					<tbody>
						<tr class="Basic-Table _idGenTableRowColumn-5">
							<td class="Basic-Table TT" colspan="5">
								<p class="table-title"><span class="table-number">&#173;</span><span class="table-number">T</span><span class="table-number">able&#160;9-1</span> Conditions Commonly Associated With Keratoconus</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-6">
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH">
								<p class="table-column-head">Associated Systemic Conditions</p>
							</td>
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH">
								<p class="table-column-head">Associated Ocular Diseases</p>
							</td>
							<td class="Basic-Table TCH" />
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-7">
							<td class="Basic-Table TBF" />
							<td class="Basic-Table TBF">
								<p class="table-body">Atopic disease</p>
							</td>
							<td class="Basic-Table TBF" />
							<td class="Basic-Table TBF">
								<p class="table-body">Vernal keratoconjunctivitis</p>
							</td>
							<td class="Basic-Table TBF" />
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Down syndrome</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Floppy eyelids</p>
							</td>
							<td class="Basic-Table TB" />
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Ehlers-&#173;Danlos syndrome</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Leber congenital amaurosis<span class="table-body_superscript _idGenCharOverride-1">a</span></p>
							</td>
							<td class="Basic-Table TB" />
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Osteogenesis imperfecta</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Retinitis pigmentosa</p>
							</td>
							<td class="Basic-Table TB" />
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-6">
							<td class="Basic-Table TBL" />
							<td class="Basic-Table TBL">
								<p class="table-body">Sleep apnea</p>
							</td>
							<td class="Basic-Table TBL" />
							<td class="Basic-Table TBL">
								<p class="table-body">Retinopathy of prematurity</p>
							</td>
							<td class="Basic-Table TBL" />
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-9">
							<td class="Basic-Table TFN" colspan="5">
								<p class="table-footnote"><span class="table-footnote_superscript _idGenCharOverride-1">a</span> Not to be confused with Leber hereditary optic neuropathy.</p>
							</td>
						</tr>
					</tbody>
				</table>
			</div>
		</div>
		
		<div id="Table 9-2">
			<div id="_idContainer048" class="Basic-Text-Frame">
				<table id="table002" class="Basic-Table">
					<colgroup>
						<col class="_idGenTableRowColumn-10" />
						<col class="_idGenTableRowColumn-11" />
						<col class="_idGenTableRowColumn-12" />
						<col class="_idGenTableRowColumn-11" />
						<col class="_idGenTableRowColumn-13" />
					</colgroup>
					<tbody>
						<tr class="Basic-Table _idGenTableRowColumn-5">
							<td class="Basic-Table TT" colspan="5">
								<p class="table-title"><span class="table-number">&#173;</span><span class="table-number">T</span><span class="table-number">able&#160;9-2</span> Complications Associated With Epi-&#173;Off&#160;CXL</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-6">
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH">
								<p class="table-column-head">117 Eyes</p>
							</td>
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH">
								<p class="table-column-head">1-&#173;Year Follow-&#173;Up</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-7">
							<td class="Basic-Table TBF">
								<p class="table-body">Loss <span class="table-body_symbol">≥</span>2 lines</p>
							</td>
							<td class="Basic-Table TBF" />
							<td class="Basic-Table TBF">
								<p class="table-body">2.9%</p>
							</td>
							<td class="Basic-Table TBF" />
							<td class="Basic-Table TBF" />
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TB">
								<p class="table-body">Progression</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">7.6%</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">3% if K <span class="table-body_symbol">&lt;</span>58.00 D</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TB">
								<p class="table-body">Sterile infiltrates</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">7.6%</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB" />
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TB">
								<p class="table-body">Central stromal scar</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">2.8%</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB" />
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-14">
							<td class="Basic-Table TBL">
								<p class="table-body">Overall complication rate</p>
							</td>
							<td class="Basic-Table TBL" />
							<td class="Basic-Table TBL">
								<p class="table-body">1% if patient <span class="table-body_symbol">&lt;</span>35&#160;years old</p>
							</td>
							<td class="Basic-Table TBL" />
							<td class="Basic-Table TBL" />
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-6">
							<td class="Basic-Table TFN" colspan="5">
								<p class="table-footnote">CXL <span class="table-footnote_symbol">=</span> corneal crosslinking; D <span class="table-footnote_symbol">=</span> diopters; K <span class="table-footnote_symbol">=</span> keratometry reading.</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-15">
							<td class="Basic-Table TFN CellOverride-1 _idGenCellOverride-1" colspan="5">
								<p class="table-footnote">Data from Koller&#160;T, Mrochen&#160;M, Seiler&#160;T. Complication and failure rates &#173;after corneal crosslinking. <br /><span class="table-source-note_italic">J Cataract Refract Surg.</span> 2009;35(8):1358–1362.</p>
							</td>
						</tr>
					</tbody>
				</table>
			</div>
		</div>
		
		<div id="Table 9-3">
			<div id="_idContainer061" class="Basic-Text-Frame">
				<table id="table003" class="Basic-Table">
					<colgroup>
						<col class="_idGenTableRowColumn-16" />
						<col class="_idGenTableRowColumn-17" />
						<col class="_idGenTableRowColumn-18" />
						<col class="_idGenTableRowColumn-17" />
						<col class="_idGenTableRowColumn-19" />
						<col class="_idGenTableRowColumn-17" />
						<col class="_idGenTableRowColumn-20" />
						<col class="_idGenTableRowColumn-17" />
						<col class="_idGenTableRowColumn-21" />
					</colgroup>
					<tbody>
						<tr class="Basic-Table _idGenTableRowColumn-22">
							<td class="Basic-Table TT" colspan="9">
								<p class="table-title"><span class="table-number">&#173;</span><span class="table-number">T</span><span class="table-number">able&#160;9-3</span> Comparison of Pellucid Marginal Degeneration With Other Peripheral Corneal Thinning Disorders</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-22">
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH">
								<p class="table-column-head">Pellucid Marginal Degeneration</p>
							</td>
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH">
								<p class="table-column-head">Terrien Marginal Degeneration<span class="table-column-head_superscript _idGenCharOverride-1">a</span></p>
							</td>
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH">
								<p class="table-column-head">Mooren Ulcer<span class="table-column-head_superscript _idGenCharOverride-1">b</span></p>
							</td>
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH">
								<p class="table-column-head">Furrow Degeneration<span class="table-column-head_superscript _idGenCharOverride-1">a</span></p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-23">
							<td class="Basic-Table TBF CellOverride-2">
								<p class="table-body"><span class="table-body_bold">Symptoms</span></p>
							</td>
							<td class="Basic-Table TBF CellOverride-2" />
							<td class="Basic-Table TBF CellOverride-2">
								<p class="table-body">Blurred vision due to astigmatism; noninflammatory</p>
							</td>
							<td class="Basic-Table TBF CellOverride-2" />
							<td class="Basic-Table TBF CellOverride-2">
								<p class="table-body">Blurred vision due to astigmatism; may be associated with inflammation</p>
							</td>
							<td class="Basic-Table TBF CellOverride-2" />
							<td class="Basic-Table TBF CellOverride-2">
								<p class="table-body">Pain, redness, and blurred vision due to inflammation early; scarring late</p>
							</td>
							<td class="Basic-Table TBF CellOverride-2" />
							<td class="Basic-Table TBF CellOverride-2">
								<p class="table-body">None</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-24">
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body"><span class="table-body_bold">Associated systemic disease</span></p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Typically none</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">May be associated with hepatitis C or helminthic disease; unlike typical PUK, which is often associated with systemic disease<span class="table-body_superscript _idGenCharOverride-1">c</span></p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">None</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-25">
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body"><span class="table-body_bold">Age</span></p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">20–40&#160;years</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Typically older than 40&#160;years</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Young individuals: more severe form; older individuals: milder form</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Older adults</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-26">
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body"><span class="table-body_bold">Sex</span></p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">No predilection</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Male predominance</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Male predominance with the bilateral form</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">No predi&#173;lection</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-25">
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body"><span class="table-body_bold">Laterality</span></p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Bilateral with asymmetry pos&#173;si&#173;ble</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Usually bilateral but may be asymmetric</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Bilateral in youn&#173;ger individuals</p>
								<p class="table-body">Unilateral in older individuals</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Bilateral</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-27">
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body"><span class="table-body_bold">Epithelial defects</span></p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Usually none</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Typical</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">None</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-28">
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body"><span class="table-body_bold">Location of thinning</span></p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Usually inferior</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Typically pre&#173;sents superiorly but may spread circumferentially; usually does not pro&#173;gress &#173;toward central cornea but may involve inferior limbus</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Typical onset is nasal or temporal, progresses circumferentially and then centrally with undermining of central edge</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Circumlimbal thinning within the arcus</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-27">
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body"><span class="table-body_bold">Vessels</span></p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Cross the area of thinning</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Stop at the peripheral edge of defect</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Not typical</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-26">
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body"><span class="table-body_bold">Lipid</span></p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">Lipid deposits at the central edge of the pannus</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TB CellOverride-3" />
							<td class="Basic-Table TB CellOverride-3">
								<p class="table-body">None except the arcus</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-29">
							<td class="Basic-Table TBL CellOverride-4">
								<p class="table-body"><span class="table-body_bold">Arcus</span></p>
							</td>
							<td class="Basic-Table TBL CellOverride-4" />
							<td class="Basic-Table TBL CellOverride-4">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TBL CellOverride-4" />
							<td class="Basic-Table TBL CellOverride-4">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TBL CellOverride-4" />
							<td class="Basic-Table TBL CellOverride-4">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TBL CellOverride-4" />
							<td class="Basic-Table TBL CellOverride-4">
								<p class="table-body">Always</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-30">
							<td class="Basic-Table TFN CellOverride-5" colspan="9">
								<p class="table-footnote">PUK <span class="table-footnote_symbol">=</span> peripheral ulcerative keratitis.</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-31">
							<td class="Basic-Table TFN CellOverride-6 _idGenCellOverride-1" colspan="9">
								<p class="table-footnote ParaOverride-10"><span class="table-footnote_superscript _idGenCharOverride-1">a</span>&#9;See <span class="table-footnote_xref-local">Chapter&#160;6.</span></p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TFN CellOverride-7 _idGenCellOverride-1" colspan="9">
								<p class="table-footnote ParaOverride-10"><span class="table-footnote_superscript _idGenCharOverride-1">b</span>&#9;See <span class="table-footnote_xref-local">Chapter&#160;13.</span></p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TFN CellOverride-7 _idGenCellOverride-1" colspan="9">
								<p class="table-footnote ParaOverride-10"><span class="table-footnote_superscript _idGenCharOverride-1">c</span>&#9;See &#173;Table&#160;13-4.</p>
							</td>
						</tr>
					</tbody>
				</table>
			</div>
		</div>
		
		<div id="Table 9-4">
			<div id="_idContainer067" class="Basic-Text-Frame">
				<table id="table004" class="Basic-Table">
					<colgroup>
						<col class="_idGenTableRowColumn-32" />
						<col class="_idGenTableRowColumn-17" />
						<col class="_idGenTableRowColumn-33" />
						<col class="_idGenTableRowColumn-17" />
						<col class="_idGenTableRowColumn-33" />
						<col class="_idGenTableRowColumn-17" />
						<col class="_idGenTableRowColumn-19" />
					</colgroup>
					<tbody>
						<tr class="Basic-Table _idGenTableRowColumn-22">
							<td class="Basic-Table TT" colspan="7">
								<p class="table-title"><span class="table-number">&#173;</span><span class="table-number">T</span><span class="table-number">able&#160;9-4</span> Comparison of Keratoglobus to Other Conditions in the Differential Diagnosis</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-6">
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH">
								<p class="table-column-head">Keratoglobus</p>
							</td>
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH">
								<p class="table-column-head">Megalocornea<span class="table-column-head_superscript _idGenCharOverride-1">a</span></p>
							</td>
							<td class="Basic-Table TCH" />
							<td class="Basic-Table TCH">
								<p class="table-column-head">Congenital Glaucoma<span class="table-column-head_superscript _idGenCharOverride-1">a</span></p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-34">
							<td class="Basic-Table TBF">
								<p class="table-body"><span class="table-body_bold">Corneal thinning</span></p>
							</td>
							<td class="Basic-Table TBF" />
							<td class="Basic-Table TBF">
								<p class="table-body">Marked; diffuse but greatest in the periphery</p>
							</td>
							<td class="Basic-Table TBF" />
							<td class="Basic-Table TBF">
								<p class="table-body">Normal thickness</p>
							</td>
							<td class="Basic-Table TBF" />
							<td class="Basic-Table TBF">
								<p class="table-body">Normal to increased thickness</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-29">
							<td class="Basic-Table TB">
								<p class="table-body"><span class="table-body_bold">Corneal steepening</span></p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Marked; diffuse</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Normal or steep contour</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Normal contour</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TB">
								<p class="table-body"><span class="table-body_bold">Corneal edema</span></p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">None &#173;unless hydrops</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Pos&#173;si&#173;ble</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TB">
								<p class="table-body"><span class="table-body_bold">Haab striae</span></p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Common</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TB">
								<p class="table-body"><span class="table-body_bold">Corneal dia&#173;meter</span></p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Normal</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Increased</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Increased</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TB">
								<p class="table-body"><span class="table-body_bold">Increased axial length</span></p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">May be pre&#173;sent</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Usually not</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Common</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TB">
								<p class="table-body"><span class="table-body_bold">Increased&#160;IOP</span></p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">No</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">No</p>
							</td>
							<td class="Basic-Table TB" />
							<td class="Basic-Table TB">
								<p class="table-body">Pos&#173;si&#173;ble</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-22">
							<td class="Basic-Table TBL">
								<p class="table-body"><span class="table-body_bold">Optic nerve head cupping</span></p>
							</td>
							<td class="Basic-Table TBL" />
							<td class="Basic-Table TBL">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TBL" />
							<td class="Basic-Table TBL">
								<p class="table-body">None</p>
							</td>
							<td class="Basic-Table TBL" />
							<td class="Basic-Table TBL">
								<p class="table-body">Common</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-35">
							<td class="Basic-Table TFN" colspan="7">
								<p class="table-footnote">IOP <span class="table-footnote_symbol">=</span> intraocular pressure.</p>
							</td>
						</tr>
						<tr class="Basic-Table _idGenTableRowColumn-8">
							<td class="Basic-Table TFN CellOverride-7 _idGenCellOverride-1" colspan="7">
								<p class="table-footnote ParaOverride-10"><span class="table-footnote_superscript _idGenCharOverride-1">a</span>&#9;See <span class="table-footnote_xref-local">Chapter&#160;7.</span></p>
							</td>
						</tr>
					</tbody>
				</table>
			</div>
		</div>
				
		<!--<div class="_idGenObjectLayout-1">
			<div id="_idContainer041" class="_idGenObjectStyleOverride-1">
			</div>
		</div>-->
		
	</body>
</html>
